Back

Learner’s Digest International (TM)

  • Antineoplastic Agents
  • Carcinoma, Non-Small-Cell Lung
  • Neoadjuvant Therapy
  • Pathologic Complete Response
  • Treatment Expectations

Neoadjuvant Chemo-Immunotherapy in Resectable Non-Small Cell Lung Cancer

The goal of this program is to improve management of resectable non-small cell lung cancer. After hearing and assimilating this program, the clinician will be better able to:Interpret pathologic complete response to predict survival in resectable NSCLC.Use PD-L1 status to inform treatment expectations in neoadjuvant therapy.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 0.75 credits

MOC types

ABIM — Medical KnowledgeUp to 0.75 points

FDA REMS

No

Qualifies for MIPS

No

Pricing

Membership pricing — $1,095 / year

This provider prices CME through membership. Individual courses may also be sold separately.

See plans on audio-digest.org

Listed by the provider

  • Enduring / On-demand
  • Credit · Up to 0.75 credits
  • MOC · Up to 0.75 points
  • Membership pricing
  • Released
    Sep 8, 2026
  • Last day to claim credit
    Jul 22, 2029 3 years left